Optimized Clostridium-Directed Enzyme Prodrug Therapy Improves the Antitumor Activity of the Novel DNA Cross-Linking Agent PR-104
Open Access
- 30 September 2008
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 68 (19), 7995-8003
- https://doi.org/10.1158/0008-5472.can-08-1698
Abstract
We have previously shown that spores of the nonpathogenic clostridial strain C. sporogenes genetically engineered to express the E. coli–derived cytosine deaminase gene are effective in converting systemically injected nontoxic 5-fluorocytosine into the toxic anticancer drug 5-fluorouracil, thereby producing tumor-specific antitumor activity. To improve the expression of E. coli–derived genes with this system, we first replaced the original fdP promoter in the vector with one of two powerful endogenous clostridial promoters: that of the thiolase gene (thlP) and that for the clostridial transcription factor abrB310 (abrBP). These substitutions improved protein expression levels of the prodrug-activating genes by 2- to 3-fold in comparison with fdP-driven expression. However, despite these strong promoters, we found much higher expression of the nitroreductase (NTR) protein in the E. coli host compared with the clostridial host, which we hypothesized could be the result of different codon use between the two organisms. To test this, we constructed new expression vectors with an artificially synthesized NTR gene using optimized clostridial codons (sNTR). Results from both enzymatic assays and Western blots of cell extracts from clostridial transformants harboring plasmid constructs of thlP-sNTR and abrBP-sNTR showed that the expression and activity of the NTR gene product was increased by ∼20-fold compared with the original construct. In vivo studies with i.v. administered sNTR-expressing C. sporogenes spores in SiHa tumor–bearing mice showed significantly improved antitumor efficacy when combined with either 5-aziridinyl-2,4-dinitrobenzamide (CB1954) or the novel dinitrobenzamide mustard prodrug, PR-104. [Cancer Res 2008;68(19):7995–8003]Keywords
Other Versions
This publication has 44 references indexed in Scilit:
- The nitroreductase prodrug SN 28343 enhances the potency of systemically administered armed oncolytic adenovirus ONYX-411NTRCancer Gene Therapy, 2007
- Repeated cycles of Clostridium-directed enzyme prodrug therapy result in sustained antitumour effects in vivoBritish Journal of Cancer, 2006
- New enzyme for reductive cancer chemotherapy, YieF, and its improvement by directed evolutionMolecular Cancer Therapeutics, 2006
- Pharmacologic and Toxicologic Evaluation of C. novyi-NT SporesToxicological Sciences, 2005
- Expression of abrB310 and sinR , and Effects of Decreased abrB310 Expression on the Transition from Acidogenesis to Solventogenesis, in Clostridium acetobutylicum ATCC 824Applied and Environmental Microbiology, 2005
- Tumor-Targeted Salmonella Expressing Cytosine Deaminase as an Anticancer AgentHuman Gene Therapy, 2002
- Bifidobacterium longum as a delivery system for cancer gene therapy: Selective localization and growth in hypoxic tumorsCancer Gene Therapy, 2000
- Anaerobic bacteria as a gene delivery system that is controlled by the tumor microenvironmentGene Therapy, 1997
- Chemotherapeutic tumour targeting using clostridial sporesFEMS Microbiology Reviews, 1995
- Clostridial oncolysis in manEuropean Journal of Cancer (1965), 1967